EastWest Bioscience announced the appointment of an exceptional team of retail advisors effective January 1, 2019, an active retail advisory board (the "Advisory") to help with the next stage development of Eastwest's retail model, product development, and the recently acquired Sangster's Health Centres ("Sangster's"). The board will work with the management of Eastwest and Sangster's to add strategic strength to Sangster's management and the Company's product development and distribution. The Advisory has experience including franchise development, corporate and franchise finance, retail management for both brick and mortar stores and on-line platforms, as well as top-tier Canadian consumer markets experience. The Advisory will be instrumental in developing the critical infrastructure, personnel and management resources to take the iconic Sangster's brand to a new level of Sangster's Health Superstores. The long-term vision for Sangster's is the development of proposed medical clinics. These are intended to pave the way for Sangster's to license and sell pharmaceutical products as well as participate in the medical marijuana market with primarily CBD-infused products. Although the board may be expanded in the future, the current Advisory is expected to include Steve Langford, Helen Langford, and Thomas Kim, each with strong but unique retail and multi-branch store experience.